Cizzle Biotechnology annual report now available

Cizzle Biotechnology Holdings

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics developer, has announced that copies of the annual report and accounts for the year ended 31 December 2021, together with the notice of Annual General Meeting (“AGM”), have been sent to shareholders and are available for viewing on the Company’s website and below.

The AGM of Cizzle Biotechnology will be held at 11.00 a.m. BST on 27 June 2022 at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street, London, EC3V 0HR.

Cizzle Biotechnology is developing a blood test for the early detection of lung cancer.  Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues.  Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:
    Cizzle Biotechnology appoints Matt Bower as Non-Executive Director, enhancing its board for growth as it prepares to launch innovative cancer tests globally.
    Cizzle Biotechnology announces a breakthrough in early lung cancer detection with iGenomeDX appointed to launch the CIZ1B biomarker test across the USA.
    Cizzle Biotechnology names Professor Dawn Coverley as Chief Scientific Officer, marking a strategic shift. She will focus on advancing the CIZ1B biomarker assay.
    Cizzle Biotechnology expands its CIZ1B biomarker test agreement to the Caribbean, accelerating market entry for early lung cancer detection in 2025.
    Discover how Cizzle Biotechnology's innovative CIZ1B biomarker is revolutionizing early lung cancer detection and leveraging strategic partnerships.
    Cizzle Biotechnology's Dr Allan Syms discusses a pivotal licensing deal for the CIZ1B biomarker, enhancing early lung cancer detection strategies.

      Search

      Search